When associated with ningetinib, another TKI used in NSCLC, it did not affect the pharmacokinetics of the latter, although it is metabolized by CYP1A1, but more safety studies should be performed on NSCLC patients [48]. Here, CYP1A1 is linked to non-small cell lung carcinoma.